Chemically modified neoantigen-based immunotherapy for targeting KRAS^G12C-driven tumors

Area of Science:

• Oncology
• Immunology
• Drug Development

Background:

• KRAS G12C mutations drive various cancers, and targeted therapies show promise but are hampered by resistance.
• Developing durable treatment strategies for KRAS G12C-driven malignancies remains a significant clinical challenge.

Approach:

• This review explores novel strategies unifying KRAS G12C-targeted therapy with immunotherapy.
• These approaches utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens.
• The engineered neoantigens facilitate the targeting and destruction of drug-resistant cancer cells via hapten-based immunotherapeutics.

Key Points:

• Resistance mechanisms limit the efficacy and durability of current KRAS G12C-targeted drugs.
• Combining targeted therapy with immunotherapy offers a promising avenue to overcome resistance.
• Engineered peptide/MHC complexes serve as neoantigens to direct immune responses against resistant clones.

Conclusions:

• Unifying KRAS G12C-targeted therapy and immunotherapy presents a viable strategy to enhance treatment outcomes.
• Hapten-based immunotherapeutics, guided by neoantigen presentation, can effectively eliminate resistant cancer cells.
• This approach holds potential for durable clinical responses in KRAS G12C-mutant cancers.